Drug Watch

Drug Watch

The latest on the biggest pipeline moves.

How Infusion Centers Support Dermatology Research
June 19, 2022

Lindsey Savickas, RN, BSN, and COO at Infusion Associates, explains how infusion centers can support researchers in the dermatology space in discovering more effective treatments.

POLL: Which Recent FDA Update Was Most Exciting?
June 15, 2022

Click here to answer this week's poll.

Baricitinib FDA Approved to Treat Alopecia Areata
June 13, 2022

This marks the first FDA approval of a systemic treatment for alopecia areata.

Factors Affecting Patients Adherence in Topical Therapies
June 07, 2022

Education, honesty, and communication skills are key for both patient and dermatologist when it comes to creating treatment regimens.

TMB-001 Granted FDA Breakthrough Therapy Designation
May 31, 2022

Timber Pharmaceuticals has received an FDA breakthrough therapy designation for TMB-001 for the treatment of congenital ichthyosis.

FDA Grants Priority Review for Dupilumab sBLA for Adults with Prurigo Nodularis
May 31, 2022

Dupilumab (Dupixent; Sanofi and Regeneron Pharmaceuticals, Inc) has received priority review for its supplemental Biologics License Application by the FDA to treat adult patients with prurigo nodularis.

Tapinarof Cream 1% is FDA Approved
May 24, 2022

Dermavant’s new topical treatment for plaque psoriasis in adults was approved by the FDA this morning.

FDA Grants Fast Track Designation to TMB-001
April 28, 2022

The designation is for the treatment of X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis lamellar ichthyosis (ARCI-LI).

FDA Accepts BLA Resubmission for DAXI Injections
April 22, 2022

Revance Therapeutics announces the FDA has accepted the resubmission for daxibotulinumtoxinA for injection of glabellar lines.

Enrollment in ARRECTOR Pivotal Phase 3 Trial Completed
April 21, 2022

Arcutis Biotherapeutics announced news of its topical roflumilast foam’s trial on safety and efficacy of treatment in scalp and body psoriasis.